Prokinecitine in Acute Myocardial Infarction

Pilot Study Prok-Idm: Interest of Dosage of Prokinecitine in Acute Myocardial Infarction

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02021487

Acronym

Prok-Idm

Enrollment

172

Registered

2013-12-27

Start date

2013-11-30

Completion date

2019-02-28

Last updated

2019-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST Elevatation Myocardial Infarction (STEMI)

Brief summary

The study aims to investigate the presence of a substance in the blood called prokinecitine, which is released by the heart when a heart attack occurs. Several venous blood samples at the arm are withdrawn at admission, H6, H12, H24, H48 and H72 in order to measure the concentration of this substance in the blood. The usefulness of this new blood marker is going to be determsined to seek if it would be of help to better diagnose or estimate the gravity of heart infarction after a heart attack.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with acute St elevation myocardial infarction of less than 6 hours * Age\>18 y/o

Exclusion criteria

* Previous myocardial infarction * LBB, RBB * Renal Insuffiency MDRD\<30 mL/min * Patient with Pace-Maker or ICD.

Design outcomes

Primary

Measure	Time frame	Description
Infarct size by MRI necrotic myocardial mass	7 days	Infarct size by MRI necrotic myocardial mass

Countries

France

Outcome results